Cost-effectiveness analysis (CEA) changes that dynamic. It gives decision-makers a reproducible, evidence-backed framework for determining which interventions, programs, and vendor contracts deliver the most health value per dollar spent. Organizations that use it consistently don't just save money — they make better decisions.
This article walks through what CEA is, why it matters, how to run one, and what a real-world healthcare scenario looks like when the method is applied correctly.
TL;DR
- CEA compares the cost of a healthcare intervention against the health outcomes it produces, always measured relative to an alternative option.
- The core metric is the Incremental Cost-Effectiveness Ratio (ICER): cost difference divided by outcome difference between two options.
- Beyond clinical decisions, procurement, vendor selection, and operational spending all benefit from the same CEA framework.
- The process covers six steps: define the decision, quantify costs, measure outcomes, calculate the ratio, run sensitivity analysis, then act.
- U.S. healthcare wastes an estimated $760–$935 billion annually; CEA is one of the few tools that systematically identifies where that waste lives.
What Is Cost-Effectiveness Analysis in Healthcare?
CEA is a systematic comparison of two or more interventions or spending options — measuring what each costs relative to the health outcomes it produces. The key word is comparative. An intervention isn't cost-effective in the abstract; it's cost-effective relative to the alternative.
CEA vs. Cost-Benefit Analysis
The distinction matters, especially in healthcare. Cost-benefit analysis (CBA) converts everything — including health outcomes — into monetary terms to produce a net return figure. CEA keeps health outcomes in their natural units: lives saved, hospitalizations prevented, or avoided complications.
That distinction carries real ethical weight. Assigning a dollar value to a year of human life raises questions most health systems would rather not answer publicly. CEA sidesteps that problem by measuring outcomes in health units instead of dollars, making it the dominant method for healthcare resource allocation.
The Two Main Outcome Metrics
| Metric | What It Measures | Best Used For |
|---|---|---|
| QALYs (Quality-Adjusted Life Years) | Length of life weighted by quality of life | Intervention comparison, policy appraisal |
| DALYs (Disability-Adjusted Life Years) | Years of full health lost to disease | Disease burden, population health planning |
One QALY equals one year of life in perfect health — a straightforward concept that gets complicated quickly when measuring partial health states. DALYs run in the opposite direction: higher is worse, measuring burden rather than benefit.
The same cost-per-outcome logic extends beyond clinical settings. Any organizational spending decision — from staffing models to procurement contracts — can be evaluated through this lens, as long as the outcome being measured is clearly defined.
Why CEA Matters for Healthcare Priority Setting
The core problem is simple: healthcare needs are unlimited, but budgets aren't. Without a structured prioritization method, spending decisions get made based on whoever has the loudest advocate, the most recent headline, or the most political capital.
The cost of that dysfunction is measurable. Shrank et al. (JAMA, 2019) estimated total annual waste in the U.S. healthcare system at $760 billion to $935 billion — roughly 25% of all health expenditures. The IOM's earlier estimate attributed $210 billion annually to unnecessary services alone.
CEA directly addresses this by giving decision-makers an objective basis for comparison.
What CEA Delivers
- Objective comparison — removes gut-feel from resource allocation decisions
- Disinvestment identification — surfaces low-value programs eligible for reduction or elimination
- Budget justification — provides evidence-backed rationale that holds up to scrutiny
- Equity analysis — reveals which populations benefit most (and least) from a given spend
- Long-term planning — distinguishes interventions that save money over time from those that cost more
- Clinical-operational alignment — connects procurement and supply chain decisions to health outcomes
The Regulatory Pressure Is Real
CEA has become a baseline expectation for funding and coverage decisions — not an optional analytical exercise. NICE in the UK requires cost-effectiveness evidence before approving treatments, and recently confirmed it will raise its standard threshold from £20,000–£30,000 to £25,000–£35,000 per QALY starting April 2026 — the first change in 20 years.
The U.S. has no single government-mandated threshold, but benchmarks have shifted substantially. By 2021, approximately 60% of published cost-utility analyses used $100,000/QALY or higher — up from near-universal use of $50,000/QALY in the 1990s. ICER now applies $100,000–$150,000/QALY as its standard range.
The Second Panel on Cost-Effectiveness in Health and Medicine recommends presenting results at $50K, $100K, and $150K thresholds to reflect the full range of decision contexts.
How Healthcare CEA Works: A Step-by-Step Breakdown
CEA follows a clear sequence. Understanding each stage helps organizations avoid the most common mistakes: comparing without a baseline, skipping sensitivity testing, or treating CEA as a one-time exercise.
Step 1 – Define the Decision and Comparators
Specify exactly what's being decided — which of two screening programs to fund, which vendor contract offers better value, whether to expand a care coordination program. Then identify the comparator: usually the current standard of care or status quo.
Without a defined comparator, CEA produces nothing. The analysis is always relative.
Step 2 – Identify and Quantify Costs
List all relevant costs for each option:
- Direct costs — staff, equipment, drugs, technology, implementation
- Indirect costs — patient time, caregiver burden, productivity losses
- Averted costs — medical expenses avoided if the intervention works
The most common mistake here is stopping at implementation costs. Averted downstream costs — ER visits prevented, hospitalizations avoided — often reverse the apparent cost burden of a more expensive upfront intervention.
Step 3 – Measure Health Outcomes
Select the appropriate outcome unit and apply it consistently across all options being compared:
- Clinical decisions → QALYs gained, cases prevented, deaths averted
- Operational decisions → error rates, turnaround times, cost per unit processed
Outcome measurement must be consistent. Mixing metrics across options produces distorted rankings that lead to bad decisions.
Step 4 – Calculate the Cost-Effectiveness Ratio
The formula: Net Cost ÷ Change in Health Outcomes = Cost-Effectiveness Ratio
When comparing two active interventions, use the ICER:
ICER = (Cost of Option A – Cost of Option B) ÷ (Outcomes of Option A – Outcomes of Option B)
Two possible results:
- Dominance — one option is cheaper and more effective; it automatically wins, no further analysis needed
- Trade-off — one option is more effective but also more costly; the ICER tells you what you're paying per additional unit of health benefit
Step 5 – Apply Sensitivity Analysis
CEA estimates are projections, not certainties. Sensitivity analysis tests how robust the findings are by varying key assumptions — discount rates, outcome probabilities, cost estimates — and observing whether the recommendation holds.
NICE requires probabilistic sensitivity analysis before acting on findings, and the Second Panel recommends both deterministic and probabilistic approaches. Organizations that skip this step risk locking in resource allocation decisions based on assumptions that break down under real cost and outcome variation.
Step 6 – Interpret and Act on Results
Translate findings into a prioritized decision:
- Which interventions fall below acceptable thresholds → expand or fund
- Which exceed thresholds → defer or discontinue
- Where uncertainty is too high → collect more data before committing
CEA findings should be revisited as costs, outcomes, and organizational priorities shift. Build in scheduled reviews so the analysis continues to inform decisions rather than collecting dust after the initial report.
CEA in Practice: A Healthcare Scenario Walkthrough
A regional hospital system is allocating a fixed annual budget to manage high-risk diabetic patients. Two options are on the table: a remote monitoring program (CGM with remote patient monitoring) versus an expanded in-person care coordination program.
Cost Identification
The remote monitoring program carries higher upfront technology costs — device procurement, data infrastructure, staff training. The in-person program requires additional care coordinators and facility time.
Averted costs change the picture. A 2024 meta-analysis of 27 studies covering 10,124 patients found remote health monitoring reduced all-cause hospitalizations by 18% and ED visits by 15%.
Against a backdrop of $80 billion in annual diabetes inpatient costs and $10.1 billion in ED costs nationally, those reductions translate into substantial avoided spending at the system level. Once averted hospitalizations are subtracted, the apparent cost burden of the remote program drops significantly.
Outcome Measurement
The outcome metric: diabetic complications prevented per 100 patients per year. Published clinical evidence provides effectiveness estimates for each option.
A 2026 Diabetes Care study found that CGM with remote patient monitoring produced an ICER of $27,800 per QALY versus self-monitoring alone — well below all commonly cited U.S. thresholds of $50,000 to $150,000/QALY. The program increased QALYs by 0.37 and costs by $10,300 over a 20-year horizon.
Applying the Analysis
In this scenario, the remote monitoring program is more effective and, once averted costs are included, competitive on net cost. Under most scenarios, it outright dominates the in-person expansion. Sensitivity analysis confirms the robustness:
- Pessimistic case (10% hospitalization reduction): ICER rises to ~$45,000/QALY — still below every major U.S. threshold
- Base case (18% reduction): ICER holds at $27,800/QALY, well within payer-acceptable range
- Board presentation test: The recommendation holds across all tested assumptions, not just favorable ones
The concrete recommendation: Fund the remote monitoring program, track hospitalization and ED visit rates as primary outcome metrics, and set a 12-month performance review to validate assumptions against actual results.
When the numbers hold under stress-testing, the case for investment moves from analysis to action.
How Business Solutions Group Can Help
CEA requires accurate cost data as its foundation. An analysis built on incomplete or uncategorized cost information produces unreliable outputs — and unreliable outputs lead to the same reactive spending decisions CEA is meant to replace.
Business Solutions Group works with healthcare organizations to build the cost visibility that effective decision-making requires. BSG's spend intelligence software and benchmark analysis capabilities surface categorized cost data across procurement and vendor categories, making it possible to compare options with the specificity CEA demands.
On the healthcare cost side, BSG's advisory practice helps employers reduce healthcare costs by 30% to 70% — with clients typically saving $100 to $300+ per employee per month. Rather than managing premiums at the surface level, BSG addresses the root causes of cost inflation:
- Exposing billing and utilization practices that drive up healthcare spending
- Providing access to wholesale pricing structures
- Implementing IRS-compliant arrangements that reduce certain payroll taxes
Realizing those savings requires more than a one-time analysis. BSG's Client Success Team provides ongoing program management — weekly, monthly, or quarterly reporting — to track whether savings are being realized and surface new optimization opportunities as costs evolve.
For organizations ready to apply the same discipline to spending decisions that clinical teams bring to treatment selection, BSG provides the tools, benchmarks, and advisory support to make that shift.
Frequently Asked Questions
What is a cost-effectiveness analysis?
CEA is a method of comparing the cost and health outcomes of two or more interventions or spending options to determine which delivers the most value per unit of health gained. It is always comparative — an intervention can only be considered cost-effective relative to a defined alternative.
What is the main objective of cost-effectiveness analysis?
The primary goal is to help decision-makers allocate limited resources to interventions that produce the greatest health benefit per dollar spent. It replaces reactive or politically driven budget decisions with evidence-based prioritization.
What are the 5 steps of cost-benefit analysis?
CBA converts all costs and benefits into monetary terms. The core steps are: define the project scope, identify all costs and benefits, assign monetary values to each, calculate net benefit or return, and make a go/no-go decision.
What is the difference between cost-effectiveness analysis and cost-benefit analysis?
CBA converts everything — including health outcomes — to monetary value to calculate a net return. CEA keeps outcomes in their natural units (lives saved, QALYs gained), making it the preferred method in healthcare where placing a dollar value on human life raises ethical challenges.
What is an incremental cost-effectiveness ratio (ICER)?
The ICER is the difference in cost between two interventions divided by the difference in their health outcomes. In practical terms: how much extra must be spent to gain one additional unit of health benefit compared to standard care?
How do healthcare organizations decide if an intervention is cost-effective?
Decision-makers compare the ICER against a willingness-to-pay threshold — commonly cited at $50,000 to $150,000 per QALY in the U.S. No universal threshold exists; the right benchmark depends on the health system, available budget, and competing priorities for the same resources.
